CEO Dennis Calvert of BioLargo, Inc., discusses recent revenues, adding large national accounts, and developing technologies for changing the world.
CEO Dennis Calvert of BioLargo, Inc., gives an update on 2018 sales, expanding regional adoption, and establishing infrastructure to handle client growth.
CEO Dennis Calvert of BioLargo, Inc., discusses 2nd Quarter report, plans to grow client base, and opportunities to bring in new revenues.
CEO Dennis Calvert of BioLargo, Inc., gives a detailed update on the roll out of CupriDyne Clean, wastewater treatment services, and advanced wound care.
CEO Dennis Calvert of BioLargo, Inc., discusses commercialization of multiple bio-technology products, including industrial odor control and waste water treatment.
CEO Guy Cook of Lattice Biologics Ltd., discusses relocation and development of biologic products for domestic & international markets.
Calmare Therapeutics Inc (OTCQB: CTTC) Market Cap: $5,472,567 Outstanding Shares: 28,787,831 Float: 22,315,092 Analysis: Calmare Therapeutics Inc. (OTCQB: CTTC) was three months late in filing their 10Q for 3Q16, but their most recent…
SANTA ANA, CA--(UPTICK Newswire - January 6, 2016) - BioLargo, Inc. (OTCQB: BLGO) subsidiary Clyra Medical Technologies, Inc. has successfully concluded a financing from Sanatio Capital LLC for $750,000 in equity…